Catheter Precision (VTAK) Debt to Equity (2017 - 2026)

Name: Catheter Precision (VTAK) Debt to Equity (2017 - 2026) | Business Quant
Creator: Business Quant

Catheter Precision (VTAK) reported Debt to Equity of $0.04 for Q1 2026, down 84.59% on a QoQ basis from $0.24 in Q4 2025.

Catheter Precision (VTAK) has 8 years of Debt to Equity data on file, last reported at $0.04 in Q1 2026.

Quarterly Debt to Equity changed N/A year-over-year to $0.04 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.04 (changed N/A YoY) and the FY2025 annual result came in at $0.24, up 84.36% from the prior year.
Debt to Equity slipped to $0.04 in Q1 2026 per VTAK's latest filing, from $0.24 in the prior quarter.
Across five years, Debt to Equity topped out at $0.4 in Q3 2023 and bottomed at $0.04 in Q1 2026.
The 4-year median for Debt to Equity is $0.21 (2023), against an average of $0.23.
Peak annual rise in Debt to Equity reached 84.36% in 2025, while the deepest fall reached 84.36% in 2025.
Tracing VTAK's Debt to Equity over 4 years: stood at $0.4 in 2023, then plunged by 67.19% to $0.13 in 2024, then surged by 84.36% to $0.24 in 2025, then tumbled by 84.59% to $0.04 in 2026.
Per Business Quant, the three latest VTAK Debt to Equity figures stand at $0.04 (Q1 2026), $0.24 (Q4 2025), and $0.2 (Q3 2025).

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	152.82 Bn	146.17 Bn	6.27 Bn	0.65
2	Stryker	115.07 Bn	112.19 Bn	3.81 Bn	0.64
3	Medtronic	95.25 Bn	87.08 Bn	5.76 Bn	0.57
4	Boston Scientific	71.38 Bn	70.17 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	51.08 Bn	47.41 Bn	1.29 Bn	0.06
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
7	Dexcom	28.84 Bn	27.72 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.56 Bn	26.49 Bn	1.98 Bn	0.95
9	Steris	20.71 Bn	20.30 Bn	697.10 Mn	0.27
10	Catheter Precision	2.01 Mn	1.20 Mn	390,000.00	0.04

Download Data 🔒